Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1]
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al..
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis..
N Eng J Med. , 321 (1989), pp. 1494-500
[2]
Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al..
Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C..
Hepatology. , 21 (1995), pp. 639-44
[3]
Orland JR, Wright TL, Cooper S..
Acute Hepatitis C..
Hepatology. , 33 (2001), pp. 321-7
[4]
Solà R..
Tratamiento de la hepatitis aguda C..
Gastroenterol Hepatol. , 29 (2006), pp. S163-7
[5]
Camma C, Almasio P, Craxi A..
Interferon as treatment for acute hepatitis C. A meta-analysis..
Dig Dis Sci. , 41 (1996), pp. 1248-55
[6]
Quin JW..
Interferon therapy for acute hepatitis C viral infectiona review by meta-analysis..
Aust N Z J Med. , 27 (1997), pp. 611-7
[7]
Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T..
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naïve patients: 1999 update..
J Viral Hepat. , 8 (2001), pp. 48-62
[8]
Alberti A, Boccato S, Vario A, Benvegnu L..
Therapy of acute hepatitis C..
Hepatology. , 36 (2002), pp. S195-200
[9]
Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C..
When and how to treat acute hepatitis C? J Hepatol..
, 39 (2003), pp. 1056-62
[10]
Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al..
Treatment of acute hepatitis C with interferon alpha-2b..
N Engl J Med. , 345 (2001), pp. 1452-7
[11]
Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al..
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study..
Hepatology. , 43 (2006), pp. 250-6
[12]
Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al..
Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics..
Hepatology. , 39 (2004), pp. 1721-31
[13]
Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al..
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response..
Gastroenterology. , 130 (2006), pp. 632-8
[14]
Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al..
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load..
Hepatology. , 37 (2003), pp. 60-4
[15]
Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, et al..
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C..
J Hepatol. , 42 (2005), pp. 323-8
[16]
De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Calleri G, et al..
Twelve-week treatment of acute hepatitis C virus with pegylated interferon alpha 2b in injection drug users..
Clin Infect Dis. , 45 (2007), pp. 583-8
[17]
Nguyen OK, Dore GJ, Kaldor JM, Hellard ME; ATAHC Protocol Steering Committee..
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study..
Int J Drug Policy. , 18 (2007), pp. 447-51
[18]
Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al..
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience..
J Viral Hepat. , 13 (2006), pp. 256-63
[19]
Schmilovitz-Weiss H, Ben-Hari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, et al..
Lamivudine treatment for acute severe hepatitis B: a pilot study..
Liver Int. , 24 (2004), pp. 547-51
[20]
Kumar M, Satapathi S, Monga R, Das K, Hissar S, Pande C, et al..
A randomized controlled trial of lamivudine to treat acute hepatitis B..
Hepatology. , 45 (2007), pp. 97-101
[21]
Kumar M, Sarin SK, Sharma BC..
Treating acute hepatitis B..
Hepatology. , 46 (2007), pp. 607-8
